Stockscreener 앱 받기
219.53
1.27%
-2.82
시간 외 거래:
219.53
전일 마감가:
$222.35
열려 있는:
$220.53
하루 거래량:
401.20K
Relative Volume:
0.46
시가총액:
$10.80B
수익:
$4.06B
순이익/손실:
$413.08M
주가수익비율:
27.41
EPS:
8.01
순현금흐름:
$560.48M
1주 성능:
+0.61%
1개월 성능:
+7.79%
6개월 성능:
+24.08%
1년 성능:
+32.37%
1일 변동 폭
$219.46
$224.78
1주일 범위
$217.57
$228.39
52주 변동 폭
$91.86
$228.88
Charles River Laboratories International Inc Stock (CRL) Company Profile
명칭
Charles River Laboratories International Inc
전화
781-222-6000
주소
251 BALLARDVALE ST, WILMINGTON, MA
CRL을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
CRL
Charles River Laboratories International Inc
|
219.53 | 10.94B | 4.06B | 413.08M | 560.48M | 8.01 |
|
TMO
Thermo Fisher Scientific Inc
|
623.91 | 235.43B | 43.74B | 6.58B | 6.11B | 17.31 |
|
DHR
Danaher Corp
|
235.75 | 167.20B | 24.27B | 3.50B | 5.02B | 4.8589 |
|
IDXX
Idexx Laboratories Inc
|
694.75 | 55.72B | 4.17B | 1.03B | 940.22M | 12.61 |
|
IQV
Iqvia Holdings Inc
|
241.04 | 40.77B | 15.90B | 1.28B | 2.21B | 7.2842 |
|
A
Agilent Technologies Inc
|
135.95 | 38.46B | 6.95B | 1.30B | 1.15B | 4.5696 |
Charles River Laboratories International Inc Stock (CRL) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2025-12-15 | 업그레이드 | BofA Securities | Neutral → Buy |
| 2025-11-17 | 업그레이드 | Argus | Hold → Buy |
| 2025-11-06 | 업그레이드 | Robert W. Baird | Neutral → Outperform |
| 2025-10-06 | 업그레이드 | William Blair | Mkt Perform → Outperform |
| 2025-10-02 | 업그레이드 | Barclays | Equal Weight → Overweight |
| 2025-09-09 | 업그레이드 | Jefferies | Hold → Buy |
| 2025-07-09 | 업그레이드 | Citigroup | Neutral → Buy |
| 2025-05-23 | 업그레이드 | Redburn Atlantic | Neutral → Buy |
| 2025-05-14 | 업그레이드 | TD Cowen | Hold → Buy |
| 2025-05-08 | 업그레이드 | Evercore ISI | In-line → Outperform |
| 2025-03-21 | 다운그레이드 | Goldman | Buy → Neutral |
| 2025-03-04 | 업그레이드 | Citigroup | Sell → Neutral |
| 2025-03-03 | 업그레이드 | Redburn Atlantic | Sell → Neutral |
| 2025-01-22 | 다운그레이드 | William Blair | Outperform → Mkt Perform |
| 2025-01-17 | 다운그레이드 | UBS | Buy → Neutral |
| 2024-11-18 | 다운그레이드 | CLSA | Hold → Underperform |
| 2024-11-07 | 업그레이드 | CLSA | Underperform → Hold |
| 2024-10-23 | 개시 | CLSA | Underperform |
| 2024-10-14 | 개시 | Redburn Atlantic | Sell |
| 2024-10-07 | 다운그레이드 | Evercore ISI | Outperform → In-line |
| 2024-10-02 | 다운그레이드 | BofA Securities | Buy → Neutral |
| 2024-10-01 | 다운그레이드 | Citigroup | Neutral → Sell |
| 2024-08-08 | 다운그레이드 | JP Morgan | Overweight → Neutral |
| 2024-08-08 | 다운그레이드 | Robert W. Baird | Outperform → Neutral |
| 2024-06-28 | 다운그레이드 | Argus | Buy → Hold |
| 2024-06-07 | 개시 | Mizuho | Neutral |
| 2024-06-06 | 개시 | Goldman | Buy |
| 2024-02-15 | 다운그레이드 | Guggenheim | Buy → Neutral |
| 2023-09-13 | 개시 | TD Cowen | Market Perform |
| 2023-07-10 | 다운그레이드 | Citigroup | Buy → Neutral |
| 2023-02-23 | 업그레이드 | Guggenheim | Neutral → Buy |
| 2023-01-12 | 다운그레이드 | Jefferies | Buy → Hold |
| 2022-09-30 | 업그레이드 | Jefferies | Hold → Buy |
| 2022-08-25 | 개시 | Credit Suisse | Outperform |
| 2022-08-04 | 다운그레이드 | Morgan Stanley | Overweight → Equal-Weight |
| 2022-05-24 | 개시 | Guggenheim | Neutral |
| 2022-04-25 | 다운그레이드 | Jefferies | Buy → Hold |
| 2022-04-07 | 개시 | Stephens | Overweight |
| 2022-02-17 | 재확인 | BofA Securities | Buy |
| 2022-02-17 | 업그레이드 | Citigroup | Neutral → Buy |
| 2022-02-17 | 재확인 | Deutsche Bank | Buy |
| 2022-02-17 | 재확인 | Morgan Stanley | Overweight |
| 2022-02-17 | 재확인 | UBS | Buy |
| 2021-08-05 | 재개 | Credit Suisse | Neutral |
| 2020-12-16 | 다운그레이드 | Citigroup | Buy → Neutral |
| 2020-09-10 | 업그레이드 | Jefferies | Hold → Buy |
| 2020-07-01 | 업그레이드 | BofA Securities | Neutral → Buy |
| 2020-05-13 | 업그레이드 | UBS | Neutral → Buy |
| 2020-04-21 | 다운그레이드 | Jefferies | Buy → Hold |
| 2020-03-27 | 업그레이드 | Morgan Stanley | Equal-Weight → Overweight |
| 2020-03-02 | 개시 | Deutsche Bank | Buy |
| 2020-02-18 | 업그레이드 | Wolfe Research | Peer Perform → Outperform |
| 2020-01-10 | 업그레이드 | Goldman | Neutral → Buy |
| 2020-01-08 | 개시 | Wells Fargo | Overweight |
| 2020-01-07 | 개시 | Citigroup | Buy |
| 2019-10-18 | 다운그레이드 | BofA/Merrill | Buy → Neutral |
| 2019-06-10 | 개시 | SVB Leerink | Outperform |
| 2019-04-30 | 재개 | Evercore ISI | Outperform |
| 2018-12-14 | 개시 | Deutsche Bank | Buy |
| 2018-10-09 | 개시 | UBS | Neutral |
| 2018-08-23 | 업그레이드 | Raymond James | Mkt Perform → Outperform |
| 2018-07-17 | 업그레이드 | RBC Capital Mkts | Sector Perform → Outperform |
| 2018-06-15 | 업그레이드 | KeyBanc Capital Mkts | Sector Weight → Overweight |
| 2018-02-14 | 업그레이드 | SunTrust | Hold → Buy |
모두보기
Charles River Laboratories International Inc 주식(CRL)의 최신 뉴스
A Look At Charles River Laboratories (CRL) Valuation After Recent Share Price Momentum - Yahoo Finance New Zealand
Universal Beteiligungs und Servicegesellschaft mbH Grows Stock Position in Charles River Laboratories International, Inc. $CRL - MarketBeat
Charles River Laboratories International, Inc. $CRL Shares Acquired by Cooke & Bieler LP - MarketBeat
What is the Moat Score of Charles River Laboratories International Inc.2025 AllTime Highs & Verified Stock Trade Ideas - mfd.ru
Charles River Labs Reshapes Gene Therapy Role While Legal Risks Linger - simplywall.st
Is Charles River Laboratories stock underperforming the Dow? - MSN
Charles River Laboratories International (NYSE:CRL) Downgraded to Hold Rating by Wall Street Zen - MarketBeat
Charles River Laboratories International, Inc. (NYSE:CRL) Receives Consensus Recommendation of "Moderate Buy" from Analysts - MarketBeat
77,056 Shares in Charles River Laboratories International, Inc. $CRL Bought by Rakuten Investment Management Inc. - MarketBeat
Charles River and Gazi University partner on gene therapy research By Investing.com - Investing.com Australia
Charles River Laboratories Schedules Fourth-Quarter 2025 Earnings and 2026 Guidance Release and Conference Call - FinancialContent
Charles River, Gazi University Partner to Develop Advanced Therapies - Contract Pharma
Charles River (CRL) Expands Gene Therapy Collaboration with Gazi University - GuruFocus
Charles River and Gazi University partner on gene therapy research - Investing.com
Charles River Enters Manufacturing Collaboration with Gazi University - Business Wire
Charles River Laboratories Investigation Initiated: Kahn Swick & Foti, LLC Investigates the Officers and Directors of Charles River Laboratories International, Inc.CRL - PR Newswire
LaPlume of Charles River Labs sells $65k in stock By Investing.com - Investing.com Australia
Joseph Laplume Sells 400 Shares of Charles River Laboratories International (NYSE:CRL) Stock - MarketBeat
LaPlume of Charles River Labs sells $65k in stock - Investing.com
Charles River CEO Jim Foster to retire in May 2026 after 50-year career - Investing.com Nigeria
What to expect from Charles River Laboratories’ next quarterly earnings report - MSN
What Can Investors Anticipate in the Upcoming Quarterly Earnings Release From Charles River Laboratories - Bitget
Mizuho Markets Americas LLC Takes Position in Charles River Laboratories International, Inc. $CRL - MarketBeat
Palmetto Grain Brokerage - Palmetto Grain Brokerage
What to Expect From Charles River Laboratories’ Next Quarterly Earnings Report - Yahoo Finance
Buyback Watch: Will Dune Acquisition Corporation Equity Warrant benefit from rate cutsQuarterly Growth Report & Daily Risk Controlled Trade Plans - baoquankhu1.vn
Should Charles River (CRL) Leadership Shift and M&A Push Reshape Its Innovation-Led Growth Strategy? - simplywall.st
Nordea Investment Management AB Invests $5.64 Million in Charles River Laboratories International, Inc. $CRL - MarketBeat
Is Charles River Laboratories (CRL) Pricing Reflect Recent Gains And Drug Discovery Contract Momentum - Yahoo Finance
Campbell & CO Investment Adviser LLC Acquires 8,505 Shares of Charles River Laboratories International, Inc. $CRL - MarketBeat
Aug Reactions: What is the next catalyst for Charles River Laboratories International IncJuly 2025 Pullbacks & Short-Term High Return Ideas - baoquankhu1.vn
Here's Why Charles River Laboratories (CRL) is a Great Momentum Stock to Buy - sharewise.com
Analysts Offer Insights on Healthcare Companies: Irhythm Technologies (IRTC), Charles River Labs (CRL) and Butterfly Network (BFLY) - The Globe and Mail
Charles River Laboratories stock hits 52-week high at $222.78 By Investing.com - Investing.com Australia
CRL: Strategic divestitures, acquisitions, and biotech demand recovery drive a positive 2026 outlook - TradingView — Track All Markets
Charles River Laboratories International Seeks Acquisitions - marketscreener.com
Charles River Labs, Boston Scientific announce acquisitions during JPM - The Business Journals
Charles River Laboratories International (NYSE:CRL) Reaches New 12-Month HighStill a Buy? - MarketBeat
Charles River Laboratories stock hits 52-week high at $222.78 - Investing.com
Evercore ISI Group Raises Price Target for Charles River (CRL) t - GuruFocus
Charles River (NYSE: CRL) details 2026 outlook and two acquisitions - Stock Titan
Charles River Laboratories appoints Birgit Girshick as CEO following James Foster's retirement - MSN
Charles River to buy Cambodia-based monkey supplier for $510 million - Reuters
Evercore ISI Adjusts PT on Charles River Laboratories International to $260 From $250, Maintains Outperform Rating - marketscreener.com
Charles River Labs to acquire K.F. Cambodia and PathoQuest SAS By Investing.com - Investing.com Nigeria
A Look At Charles River Laboratories (CRL) Valuation As CEO Succession Plan Takes Shape - simplywall.st
Charles River Laboratories to acquire PathoQuest SAS from SHS Capital By Investing.com - Investing.com Canada
Healthcare Specialist SHS Capital agreed to sell PathoQuest to strategic buyer Charles River Laboratories - TradingView — Track All Markets
Charles River Laboratories Provides Business Updates - PharmiWeb.com
Charles River (CRL) Advances with Strategic Acquisitions and Lea - GuruFocus
Charles River Labs to acquire K.F. Cambodia and PathoQuest SAS - Investing.com
Charles River Laboratories International Inc (CRL) 재무 분석
매출
순이익
현금흐름
주당 순 이익
1.40%
0.21%
자본화:
|
볼륨(24시간):